Barry Wendt, MD
Internal Medicine · Crestview Hills, KYNPI 1801888177
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Amgen accounts for 76.8% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $11,047, more than ten times the $504 reported in 2019. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $85.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$11K
- AbbVie$706
- AstraZeneca$618
- Exact Sciences$299
- E.r. Squibb & Sons, L.L.C.$262
- Novo Nordisk$231
- plus $1K from 28 others
What the payments were for
- Consulting fees$6,12343%
- Speaking & faculty fees$2,62618%
- Travel & lodging$1,0948%
- Food & beverage$4,45631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 40 | $10,976 |
| AbbVie(2 entities) | 34 | $706 |
| AstraZeneca | 10 | $618 |
| Exact Sciences | 7 | $299 |
| E.r. Squibb & Sons, L.L.C. | 5 | $262 |
| Novo Nordisk | 13 | $231 |
| Pfizer | 10 | $143 |
| Astellas Pharma US Inc | 2 | $137 |
| Boehringer Ingelheim | 2 | $119 |
| Gilead | 4 | $91 |
| Novartis | 1 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Lilly USA, LLC | 4 | $61 |
| Johnson & Johnson(2 entities) | 4 | $54 |
| Merck | 4 | $53 |
| Dexcom, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Boston Scientific | 2 | $30 |
| Almatica Pharma LLC | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Abbott | 1 | $19 |
| Abiomed | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,298 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $70,345 |
| EliquisApixaban | 77 | $62,643 |
| FarxigaDapagliflozin Propanediol | 37 | $43,066 |
| JanuviaSitagliptin Phosphate | 33 | $32,611 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $26,422 |
| MounjaroTirzepatide | 14 | $17,306 |
| Repatha SureclickEvolocumab | 12 | $16,637 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $9,644 |
| XareltoRivaroxaban | 11 | $9,255 |
| Spiriva HandihalerTiotropium Bromide | 14 | $9,070 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $7,908 |
| Rosuvastatin Calcium | 375 | $3,184 |
| Dexlansoprazole DrDexlansoprazole | 12 | $2,729 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 30 | $2,463 |
| Metoprolol Succinate | 168 | $2,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $231 | $70,34537 claims |
| PfizerEliquis | $143 | $62,64377 claims |
| MerckJanuvia, Janumet Xr | $53 | $59,03454 claims |
| AstraZenecaFarxiga, Symbicort | $618 | $50,97449 claims |
| Lilly USA, LLCMounjaro | $61 | $17,30614 claims |
| Johnson & JohnsonXarelto | $54 | $9,25511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Crestview Hills
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
- Sanjiv GuptaGrayson$49K
- Kelley McIntyreLouisville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.